Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025492 · ClinicalTrials.gov registry record · Phase 4
Study of Trilipix Effects on Lipids and Arteries
A Phase 4 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT01025492: Clinical Trial Phase 4 study, sponsored by University of Utah.
NCT01025492 is a Phase 4 study that was terminated before completion, run by University of Utah. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01025492, a Phase 4 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance.
Primary Outcome
Comparison of apolipoprotein A-I concentrations after 12 weeks of treatment with either Trilipix or placebo
Interventions
- DRUG placebo
- DRUG Trilipix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 4 |
Why NCT01025492 stopped before completion
NCT01025492 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01025492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01025492 about?
NCT01025492 is a clinical study titled "Study of Trilipix Effects on Lipids and Arteries". Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition...
What is the current status of trial NCT01025492?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01025492?
The interventions under investigation include: placebo (DRUG), Trilipix (DRUG).
Who is sponsoring clinical trial NCT01025492?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01025492's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia